New drug trial aims to restore skin color in vitiligo patients

NCT ID NCT07223229

Recruiting now Disease control Sponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new drug called EI-001 can help improve skin repigmentation in people with non-segmental vitiligo, a condition that causes loss of skin color. The trial will enroll 45 adults and compare the drug against a placebo to see if it safely reduces the area of affected skin. EI-001 works by calming the immune system, which is thought to be overactive and attacking pigment cells in vitiligo.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SEGMENTAL VITILIGO are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Linkou Chang Gung Memorial Hospital
RECRUITING

Taoyuan District, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••
Skin Care Research, LLC
NOT_YET_RECRUITING

Hollywood, Florida, 33021, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
U Mass Chan Medical School
WITHDRAWN

Worcester, Massachusetts, 01605, United States

Conditions

Explore the condition pages connected to this study.

NON-SEGMENTAL VITILIGO